Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNAI3 | P08754 | 6/20 | 0.57 |
| ▸ | GNAO1 | P09471 | 6/20 | 0.57 |
| ▸ | GNAI1 | P63096 | 6/20 | 0.57 |
| ▸ | MAOB | P27338 | 4/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | DRD3 | P35462 | 1/20 | 0.41 |
| ▸ | EBP | Q15125 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.41 |
| ▸ | GUSB | P08236 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17526875 | 1.00 | GNAI3 (0.57) | GNAI3GNAO1GNAI1MAOBKDM4E | |
| SCHEMBL17526660 | 1.00 | GNAI3 (0.57) | GNAI3GNAO1GNAI1MAOBKDM4E | |
| SCHEMBL19286075 | 1.00 | GNAI3 (0.57) | GNAI3GNAO1GNAI1MAOBKDM4E | |
| SCHEMBL15384676 | 1.00 | GNAI3 (0.57) | GNAI3GNAO1GNAI1MAOBKDM4E | |
| SCHEMBL17460737 | 1.00 | GNAI3 (0.57) | GNAI3GNAO1GNAI1MAOBKDM4E | |
| SCHEMBL13261424 | 0.98 | GNAI3 (0.53) | GNAI3GNAO1GNAI1MAOBKDM4E | |
| SCHEMBL10175178 | 0.91 | MAOB (0.47) | GNAI3GNAO1GNAI1MAOBDRD3 | |
| SCHEMBL6663625 | 0.91 | MAOB (0.57) | GNAI3GNAO1GNAI1MAOB | |
| SCHEMBL6656793 | 0.89 | MAOB (0.56) | GNAI3GNAO1GNAI1MAOB | |
| SCHEMBL6658550 | 0.84 | MAOB (0.56) | MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230135894-A1 | MK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-05-04 | — | — | US | disclosed |
| WO-2023278759-A1 | MK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2023-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230135894-A1 | MK2 DEGRADERS AND USES THEREOF | MKNK2, MKRN3, DUS2 | GNAI3 3437/4885GNAO1 3730/4885GNAI1 3438/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.